CLINICAL TRIALS PROFILE FOR OSPEMIFENE
✉ Email this page to a colleague
All Clinical Trials for ospemifene
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00276094 ↗ | A Clinical Study to Evaluate Ospemifene in the Treatment of Vulvar and Vaginal Atrophy in Postmenopausal Women | Completed | Hormos Medical | Phase 3 | 2006-01-01 | The purpose of this study is to determine whether ospemifene is more effective than placebo in the treatment of vulvar and vaginal atrophy (VVA) in postmenopausal women. |
NCT00276094 ↗ | A Clinical Study to Evaluate Ospemifene in the Treatment of Vulvar and Vaginal Atrophy in Postmenopausal Women | Completed | QuatRx Pharmaceuticals | Phase 3 | 2006-01-01 | The purpose of this study is to determine whether ospemifene is more effective than placebo in the treatment of vulvar and vaginal atrophy (VVA) in postmenopausal women. |
NCT00276094 ↗ | A Clinical Study to Evaluate Ospemifene in the Treatment of Vulvar and Vaginal Atrophy in Postmenopausal Women | Completed | Shionogi | Phase 3 | 2006-01-01 | The purpose of this study is to determine whether ospemifene is more effective than placebo in the treatment of vulvar and vaginal atrophy (VVA) in postmenopausal women. |
NCT00566982 ↗ | A Clinical Study to Evaluate the Safety of Ospemifene | Completed | Hormos Medical | Phase 3 | 2007-10-01 | The purpose of this study is to determine the efficacy and long-term safety of 60mg ospemifene in the treatment of VVA in postmenopausal women with intact uterus. |
NCT00566982 ↗ | A Clinical Study to Evaluate the Safety of Ospemifene | Completed | QuatRx Pharmaceuticals | Phase 3 | 2007-10-01 | The purpose of this study is to determine the efficacy and long-term safety of 60mg ospemifene in the treatment of VVA in postmenopausal women with intact uterus. |
NCT00566982 ↗ | A Clinical Study to Evaluate the Safety of Ospemifene | Completed | Shionogi | Phase 3 | 2007-10-01 | The purpose of this study is to determine the efficacy and long-term safety of 60mg ospemifene in the treatment of VVA in postmenopausal women with intact uterus. |
NCT00630539 ↗ | A Clinical Study to Evaluate the Efficacy and Safety of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women | Completed | Hormos Medical | Phase 2 | 2007-08-01 | The purpose of the study is to assess the efficacy, safety and tolerability of Ospemifene 5 mg, 15 mg, and 30 mg in the treatment of VVA in postmenopausal women to find the minimum effective dose below the lowest dose of 30 mg tested earlier in Phase II. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ospemifene
Condition Name
Clinical Trial Locations for ospemifene
Trials by Country
Clinical Trial Progress for ospemifene
Clinical Trial Phase
Clinical Trial Sponsors for ospemifene
Sponsor Name